TrialTargeted oncology2015

Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).

M Donini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.